United Therapeutics (UTHR) Announces $1 Billion Share Repurchase Program

By Hao Liu • Monday, August 04 10:42 • Permanent Link

United Therapeutics Corporation (NASDAQ: UTHR) recently announced an accelerated share repurchase (ASR) program totaling $1 billion, reflecting the company's confidence in its near-term prospects. The ASR agreements, consisting of a $500 million collared and a $500 million uncollared agreement, will involve an upfront payment of $1 billion to Citibank, N.A. on August 4, 2025.

As of July 30, 2025, United Therapeutics had approximately 45.2 million shares outstanding. The company's Chairperson and CEO, Martine Rothblatt, Ph.D., expressed confidence in the intrinsic value of the stock, citing upcoming catalysts and sustained revenue and cash flow growth. The company's capital allocation philosophy aims to balance future growth investments with returning capital to shareholders.

The final number of shares to be repurchased under the uncollared ASR will be based on the average daily volume-weighted average price per share of UTHR common stock during the term of the ASR, with the final settlement expected in the fourth quarter of 2025.

For the collared ASR, the final number of shares to be repurchased will be determined based on the average daily volume-weighted average price per share of UTHR common stock during the term of the ASR, with the final settlement expected in the first quarter of 2026.

The press release emphasizes that this ASR program does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful.

United Therapeutics is known for being the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). The company's public benefit purpose is to provide a brighter future for patients through the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. Today the company's shares have moved 7.13% to a price of $294.28. For the full picture, make sure to review UNITED THERAPEUTICS Corp's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.